多队列循环蛋白质组对主动脉瘤风险的因果效应:孟德尔随机化研究
本研究采用多队列孟德尔随机化方法,利用9项蛋白质组GWAS的pQTL和FinnGen队列的主动脉瘤GWAS数据,系统评估循环血浆蛋白对主动脉瘤的因果效应。结果鉴定出大量与胸主动脉瘤和腹主动脉瘤相关的蛋白质,部分经FDR校正后稳健,并发现共享和疾病特异性蛋白,近三分之二为可成药或潜在可成药靶点。
要点
- 循环血浆蛋白对主动脉瘤风险有因果效应,鉴定出大量潜在致病蛋白和治疗靶点。
- 胸主动脉瘤和腹主动脉瘤存在共享蛋白(如AHSG、MMP7)和疾病特异性蛋白。
- 近三分之二的相关蛋白为可成药或潜在可成药靶点,为药物开发提供参考。
核心结论
- 研究鉴定出大量潜在的新型致病蛋白和治疗靶点,为阐明主动脉瘤分子发病机制和推进药物开发提供重要参考。
- 这些发现需通过实验研究和前瞻性临床研究进一步验证。
研究设计与样本
- 采用多队列孟德尔随机化方法,pQTL来自9项已发表的蛋白质组GWAS,主动脉瘤GWAS数据来自FinnGen队列。
- 共保留4,421种蛋白质的8,285个pQTL作为工具变量。
- 使用逆方差加权、MR-Egger回归、加权中位数、加权模式和简单模式方法进行两样本MR分析。
主要发现
- 使用顺式pQTL作为工具变量,鉴定出154种蛋白质与胸主动脉瘤相关(76种保护性,78种风险性),211种与腹主动脉瘤相关(112种保护性,99种风险性)。
- 使用顺式联合反式pQTL作为工具变量,鉴定出236种蛋白质与胸主动脉瘤相关,309种与腹主动脉瘤相关。
- 部分关联经FDR校正后仍显著(FDR<0.05),代表最稳健的发现。
- 胸主动脉瘤和腹主动脉瘤蛋白质组谱比较显示共享蛋白(如AHSG、MMP7、RARRES2、THBS2、CCL25)和疾病特异性蛋白(胸主动脉瘤:OVCA2、STAT3、HPSE;腹主动脉瘤:PLAU、LPA、SERPING1、SMPDL3A)。
- Steiger滤波确认了循环蛋白到主动脉瘤的效应方向,共定位分析发现多种蛋白质与主动脉瘤共享因果变异。
临床怎么用
- 研究结果为主动脉瘤的分子发病机制提供线索,并提示大量可成药蛋白靶点,可用于 prioritization 药物开发。
局限性
- 研究结果需通过实验研究和前瞻性临床研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pathogenesis of aortic aneurysm (AA) remains unclear, and there are no effective therapeutic drugs or targets. Circulating plasma proteins are considered biomarkers of AA and potential therapeutic targets for AA. This study aimed to systematically evaluate the causal effects of plasma proteins on AA using a multicohort Mendelian randomization (MR) approach. METHODS: Protein quantitative trait loci (pQTLs) was obtained from 9 published proteome genome-wide association studies (GWASs) and AA GWAS data from the FinnGen cohort. Independent pQTLs were selected as instrumental variables (IVs). Two-sample MR analysis was performed using inverse-variance weighted, MR-Egger regression, weighted median, weighted mode, and simple mode methods. Heterogeneity and pleiotropy were assessed using Cochran's Q test, I2 statistic, MR-Egger intercept, MR-PRESSO, and Leave-one-out analysis. Steiger filtering was used to test the causal direction. Colocalization analysis and pQTL-expression quantitative trait loci overlap assessment were conducted to validate the findings. Pathway enrichment and drug target analyses were performed to explore the biological and clinical implications of the MR results. RESULTS: A total of 8,285 pQTLs for 4,421 proteins were retained as IVs. Using cis-pQTLs for IVs, MR analysis identified 154 proteins associated with thoracic aortic aneurysm (TAA; 76 protective and 78 risk factors) and 211 proteins with abdominal aortic aneurysm (AAA; 112 protective and 99 risk factors) Using cis-pQTLs combined with trans-pQTLs as IVs, MR analysis identified 236 proteins associated with TAA and 309 proteins with AAA. A subset of these associations survived false discovery rate (FDR) correction (FDR <0.05), representing the most robust findings. Comparison of the TAA and AAA proteomic profiles revealed both shared proteins (e.g., AHSG, MMP7, RARRES2, THBS2, CCL25) and condition-specific proteins (e.g., OVCA2, STAT3, and HPSE for TAA; PLAU, LPA, SERPING1, and SMPDL3A for AAA), reflecting the distinct embryonic origins and pathological drivers of these 2 conditions. Steiger filtering confirmed the expected direction of effect from circulating proteins to AA. Colocalization analysis found evidence of shared causal variants between multiple proteins and AA. Pathway enrichment analysis revealed involvement in stress response, immune regulation, cytokine-cytokine receptor interaction, and metabolic processes. Nearly two-thirds of the associated proteins were classified as druggable or potentially druggable targets. CONCLUSION: This study identified a large number of potentially novel pathogenic proteins and therapeutic targets for AA, providing important references for elucidating the molecular pathogenesis of AA and advancing drug development. These findings warrant further validation through experimental studies and prospective clinical investigations.
引用
- Ding M, Li Y, Yao S, et al. Causal Effect of Multicohort Circulating Proteome on the Risk of Aortic Aneurysm: A Mendelian Randomization Study. Ann Vasc Surg. 2026. PMID: 41895592. doi:10.1016/j.avsg.2026.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。